| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| InCube Labs, L.L.C. | 22% | $13,541,357 | 27,093,552 | MIR A IMRAN | 23 Oct 2025 | |||
| Samsara BioCapital, L.P. | 9.9% | $4,939,262 | 9,882,477 | Srinivas Akkaraju | 23 Oct 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | $4,939,262 | 9,882,477 | RA Capital Management, L.P. | 23 Oct 2025 | |||
| Invus Global Management, LLC | 10% | $4,910,990 | 9,825,911 | Raymond Debbane | 16 Oct 2025 | |||
| ARMISTICE CAPITAL, LLC | 9.9% | $3,443,000 | 6,260,000 | Armistice Capital, LLC | 30 Jun 2025 | |||
| South Cone Investments Limited Partnership | 4.9% | $1,189,121 | 2,379,194 | South Cone Investments Limited Partnership | 20 Oct 2025 | |||
| Orca Capital AG | 4.3% | -56% | $907,979 | -$1,181,941 | 1,891,623 | -57% | Orca Capital AG | 22 Jul 2025 |
As of 30 Sep 2025, 36 institutional investors reported holding 4,033,213 shares of Rani Therapeutics Holdings, Inc. - Class A Common Stock, $0.0001 par value per share (RANI). This represents 4% of the company’s total 99,823,000 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 245,284 | $331,134 | +$1,696 | $1.35 | 4 |
| 2025 Q3 | 4,033,213 | $2,015,817 | -$1,258,446 | $0.50 | 36 |
| 2025 Q2 | 6,458,632 | $3,319,783 | +$1,060,109 | $0.51 | 38 |
| 2025 Q1 | 3,609,389 | $4,577,211 | -$332,794 | $1.26 | 38 |
| 2024 Q4 | 3,818,467 | $5,231,540 | -$4,952,104 | $1.37 | 41 |
| 2024 Q3 | 5,911,071 | $12,767,865 | +$5,999,502 | $2.16 | 31 |
| 2024 Q2 | 2,893,303 | $10,992,230 | -$783,115 | $3.80 | 32 |
| 2024 Q1 | 3,453,784 | $10,741,251 | +$518,051 | $3.11 | 36 |
| 2023 Q4 | 338,679 | $1,124,414 | $3.32 | 1 | |
| 2023 Q3 | 3,207,291 | $6,961,738 | -$172,517 | $2.18 | 32 |
| 2023 Q2 | 3,227,211 | $13,256,498 | +$994,178 | $4.12 | 33 |
| 2023 Q1 | 2,999,021 | $15,474,095 | +$204,505 | $5.16 | 34 |
| 2022 Q4 | 2,885,107 | $17,023,416 | -$1,474,074 | $5.90 | 31 |
| 2022 Q3 | 3,169,785 | $30,361,447 | +$3,575,258 | $9.58 | 29 |
| 2022 Q2 | 2,818,733 | $29,031,000 | +$2,777,240 | $10.33 | 24 |
| 2022 Q1 | 2,493,930 | $33,666,000 | +$16,743,364 | $13.50 | 21 |
| 2021 Q4 | 1,240,919 | $20,288,000 | +$544,186 | $16.35 | 21 |
| 2021 Q3 | 1,097,738 | $19,563,000 | +$19,563,012 | $17.82 | 15 |